NMPA approves Roche Pharmaceuticals Padter ® united with Herceptin ® and Dossie Tatse for treatment of metastatic breast cancer patients

recently, the RochePharmaceutical(http:// announced in Chinathat The NationalMedicines(http://Supervision Authority (NMPA) has officially approved the first-line standard treatment plan for THE Paitt ® (Patojus) combined with the Hercetin ® (Quto-Zuma) and dosiache for HER2-positive metastatic breast cancer patients who have not undergone anti-HER2 treatment or chemotherapythe approval of this program, to achieve the gradual internationalization of treatment plan for PATIENTs with HER2-positive advanced breast cancer in China, will bring longer survival benefits to HER2-positive breast cancer patients, help to achieve the slow treatment of breast cancer diagnosis and treatment, so that advanced breast cancer out of the "terminal disease" is possiblePatojus mono-resistance, quto-zhu mono-anti-double-target joint dositarace is the international treatment of HER2-positive advanced breast cancer standard first-line treatmentNow Padet ® advanced breast cancer first-line indication synostication in China, not only for domestic patients is of great significance, will further promote the process of standardized diagnosis and treatment of advanced breast cancer in ChinaThe mettle ® HER2-positive first-line treatment of advanced breast cancer was approved mainly based on the results of the CLEOPATRA clinical study, which lasted up to 8 years follow-up, and the PUFFIN study from the Chinese groupCLEOPATRA studies show that patopaz mono-anti-quto-bead-combined dositarace can extend the progression-free survival (PFS) of HER2-positive patients with advanced breast cancer patients by 51%, to 18.7 months, to extend the total survival (OS) of patients by 40%, and to extend the survival period to nearly 5 yearsWith the extension of the study follow-up time, in the median follow-up 8 years (up to 10 years), patozumab mono-anti-quto-zhu-mono-resistance combined dositarace treatment group 37% of patients reached eight years of survival, significantly higher than 23% of the quto-zhu mono-resistance groupTHE PUFFIN STUDY IS A BRIDGE STUDY OF CLEOPATRA, AND THE 243 CASES OF HER2-POSITIVE ADVANCED BREAST CANCER IN THE GROUP WERE ALL CHINESE PATIENTS, AND THEY WERE FOUND IN 15 CLINICAL CENTERS ACROSS THE COUNTRYThe trends in progressionless lifetime (PFS) benefits in the PUFFIN study are consistent with global data